Display options
Cite
Buchwald H, Chute EP, Goldenberg FJ, et al. Implantable infusion pump management of insulin resistant diabetes mellitus. Ann Surg. 1985;202(3):278-82doi: 10.1097/00000658-198509000-00002.
Buchwald, H., Chute, E. P., Goldenberg, F. J., Hitchcock, C. R., Hoogwerf, B. J., Barbosa, J. J., Rupp, W. M., & Rohde, T. D. (1985). Implantable infusion pump management of insulin resistant diabetes mellitus. Annals of surgery, 202(3), 278-82. https://doi.org/10.1097/00000658-198509000-00002
Buchwald, H, et al. "Implantable infusion pump management of insulin resistant diabetes mellitus." Annals of surgery vol. 202,3 (1985): 278-82. doi: https://doi.org/10.1097/00000658-198509000-00002
Buchwald H, Chute EP, Goldenberg FJ, Hitchcock CR, Hoogwerf BJ, Barbosa JJ, Rupp WM, Rohde TD. Implantable infusion pump management of insulin resistant diabetes mellitus. Ann Surg. 1985 Sep;202(3):278-82. doi: 10.1097/00000658-198509000-00002. PMID: 4037902; PMCID: PMC1250895.
Copy Download .nbib Format: NLM
Share it on
Full text links
Wolters Kluwer Free PMC Article

Ann Surg. 1985 Sep;202(3):278-82. doi: 10.1097/00000658-198509000-00002.

Implantable infusion pump management of insulin resistant diabetes mellitus.

Annals of surgery

H Buchwald, E P Chute, F J Goldenberg, C R Hitchcock, B J Hoogwerf, J J Barbosa, W M Rupp, T D Rohde

PMID: 4037902 PMCID: PMC1250895 DOI: 10.1097/00000658-198509000-00002
Free PMC Article

Abstract

Diabetes mellitus with resistance to insulin administered subcutaneously or intramuscularly (DRIASM) is a rare and brittle form of Type I diabetes, found predominantly in young females and characterized by inadequate glycemic response to subcutaneous or intramuscular insulin administration. DRIASM leads to frequent ketoacidosis and obligatory hospitalization for administration of intravenous insulin. The use of a totally implantable infusion pump effected dramatic improvement in the treatment of five patients with this difficult form of diabetes. Frequency of clinical ketoacidosis was reduced from 37 episodes per year to 0.4 episodes per year (99%), and average in-hospital days per month were reduced from 20.8 days to 2.2 days (89%) with a mean follow-up period of 14.4 months. Cost savings were approximately +10,000 per patient month. Quality of life was greatly improved for these individuals.

Similar articles

Cited by

References

  1. Surg Forum. 1970;21:136-7 - PubMed
  2. Surg Gynecol Obstet. 1972 Jan;134(1):51-6 - PubMed
  3. Lancet. 1978 Aug 5;2(8084):283-5 - PubMed
  4. Lancet. 1978 Sep 30;2(8092 Pt 1):741 - PubMed
  5. Diabetes Care. 1978 Sep-Oct;1(5):314-25 - PubMed
  6. Diabetes. 1979 Jul;28(7):640-5 - PubMed
  7. Aust N Z J Med. 1980 Feb;10(1):56-61 - PubMed
  8. Lancet. 1980 Jun 7;1(8180):1245-6 - PubMed
  9. Lancet. 1980 Jul 12;2(8185):93-4 - PubMed
  10. Surgery. 1980 Oct;88(4):507-16 - PubMed
  11. J Clin Endocrinol Metab. 1981 Feb;52(2):177-80 - PubMed
  12. N Engl J Med. 1981 Aug 13;305(7):363-8 - PubMed
  13. Cancer. 1980 Mar 1;45(5):866-9 - PubMed
  14. N Engl J Med. 1981 Dec 3;305(23):1413-4 - PubMed
  15. Br Med J (Clin Res Ed). 1981 Nov 7;283(6301):1207-9 - PubMed
  16. N Engl J Med. 1982 Jul 29;307(5):265-70 - PubMed
  17. Diabetologia. 1982 Oct;23(4):333-6 - PubMed
  18. Diabetes. 1982 May;31(5 Pt 1):470-3 - PubMed
  19. Annu Rev Med. 1983;34:145-60 - PubMed
  20. Diabetes Care. 1983 May-Jun;6(3):279-84 - PubMed
  21. Diabetes Care. 1985 Jan-Feb;8(1):12-20 - PubMed
  22. Diabetes Res. 1984 Jul;1(2):83-8 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources